Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...

Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non–small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO ...

A2 Biotherapeutics Presents Data from EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...